PT-141 (Bremelanotide): Legal and Patent Challenges

FDA Regulatory Pathway: From Nasal Spray to Subcutaneous Injection

Bremelanotide did not take a straight line to approval. The compound's regulatory history spans nearly two decades of reformulation, clinical setbacks, and agency negotiations that shaped the product patients use today.

The Failed Intranasal Program

Palatin Technologies originally developed PT-141 as an intranasal spray for both male and female sexual dysfunction. In 2007, the FDA placed a clinical hold on the intranasal program after trial participants experienced clinically significant blood pressure elevations. Systolic readings rose by more than 20 mmHg in some subjects. The agency's concern was straightforward: a nasally absorbed peptide produced unpredictable cardiovascular spikes that could not be adequately managed with labeling alone 1.

Palatin pivoted. The company reformulated bremelanotide as a 1.75 mg subcutaneous injection, which produced a more predictable pharmacokinetic profile and smaller blood pressure changes. Mean systolic increases with the subcutaneous route were approximately 5 to 6 mmHg, peaking around 2 to 4 hours post-dose and resolving within 12 hours 2.

NDA Submission and Approval

Palatin submitted its New Drug Application (NDA 210557) in partnership with AMAG Pharmaceuticals, which had acquired North American commercial rights. The FDA accepted the NDA for priority review with a PDUFA date in early 2019. On June 21, 2019, the agency approved Vyleesi for premenopausal women with acquired, generalized HSDD 3.

The approval was narrow. FDA restricted the indication to premenopausal women only, excluded situational HSDD, and required labeling that specified a maximum of 8 doses per month. The agency did not grant a broader sexual dysfunction indication that Palatin had initially pursued.

The RECONNECT Trials: Evidence That Defined the Label

The approval rested on two identically designed Phase 3 trials collectively called RECONNECT, published in Obstetrics & Gynecology in 2019. These trials enrolled 1,247 premenopausal women with HSDD across North American sites 2.

Efficacy Outcomes

Women self-administered bremelanotide 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity. Over 24 weeks, bremelanotide produced a statistically significant increase in the Female Sexual Function Index desire domain score compared with placebo (mean difference 0.5 points, P<0.01). The co-primary endpoint, reduction in distress measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO), also reached significance 2.

The clinical meaningfulness of these changes drew debate. A 0.5-point improvement on a 6-point desire subscale is modest by any standard. FDA reviewers acknowledged this but concluded the totality of evidence, including patient-reported outcomes showing reduced personal distress, supported approval.

Safety Signals in the Key Data

Nausea was the most common adverse event, affecting approximately 40% of bremelanotide-treated patients versus 1% on placebo. About 13% of treated participants experienced flushing, and 6% reported injection site reactions. Roughly 4% of patients treated with bremelanotide developed transient skin hyperpigmentation, particularly on the face and gingiva, which the FDA flagged as a class effect of melanocortin receptor activation 4.

The cardiovascular signal that killed the nasal formulation persisted in attenuated form. The label warns that bremelanotide causes transient increases in blood pressure and decreases in heart rate, contraindicating use in patients with uncontrolled hypertension or known cardiovascular disease 3.

Patent Field and Intellectual Property Disputes

Palatin Technologies built a layered patent estate around bremelanotide covering composition of matter, synthetic peptide analogs, methods of use for sexual dysfunction, and the subcutaneous delivery system. This strategy was designed to extend market exclusivity well beyond the original compound patent.

Core Patent Holdings

Palatin's earliest patents covered cyclic peptide analogs acting on melanocortin receptors, with claims broad enough to capture PT-141 and structurally related compounds. Method-of-use patents specifically claimed subcutaneous administration for female sexual dysfunction, a narrower but tactically valuable layer of protection 5.

The composition-of-matter patents began expiring in the early 2020s, but Palatin filed continuation patents and new formulation claims intended to extend protection. The company disclosed in SEC filings that its patent portfolio for bremelanotide included patents with expiration dates ranging from 2023 through the early 2030s.

Paragraph IV Challenges and Generic Entry

No Abbreviated New Drug Application (ANDA) with a Paragraph IV certification challenging Palatin's bremelanotide patents has been publicly reported as of mid-2026. The peptide's complex manufacturing (solid-phase synthesis), the autoinjector delivery device, and modest commercial sales have likely dampened generic interest. Peptide drugs generally attract fewer generic challengers than small-molecule blockbusters because bioequivalence for injectable peptides demands more rigorous characterization than a standard oral generic.

Compounding Pharmacy Pressures

The more active legal and regulatory challenge to Vyleesi's market position comes from compounding pharmacies. PT-141 (bremelanotide acetate) has been available through 503A and 503B compounding pharmacies, often marketed for off-label male and female sexual dysfunction at substantially lower cost than the branded autoinjector.

The FDA's position on compounded bremelanotide remains an area of active enforcement. Under the Federal Food, Drug, and Cosmetic Act, 503B outsourcing facilities may compound drugs that are "essentially a copy" of an approved product only under limited circumstances. Palatin has argued that compounded PT-141 directly competes with Vyleesi and that the FDA should enforce against these copies more aggressively 6.

The 2024 expiration of initial composition-of-matter patents may have weakened Palatin's use, but the company retains method-of-use and formulation patents that could still support infringement claims against compounders producing bremelanotide specifically for HSDD.

Commercial Licensing: The AMAG Deal and Its Collapse

Palatin's commercial strategy depended heavily on a 2017 licensing agreement with AMAG Pharmaceuticals, which paid $60 million upfront for exclusive North American rights to Vyleesi. AMAG was responsible for the commercial launch, sales force deployment, and payor negotiations 7.

Why the Launch Struggled

Vyleesi launched in September 2019 at a list price of approximately $900 per dose, positioning it as a premium product in a category (HSDD) where physician awareness was low and insurance coverage was inconsistent. The drug required subcutaneous self-injection before sexual activity, a barrier that limited uptake compared with the daily oral alternative flibanserin (Addyi).

First-year sales were under $10 million. AMAG's own financial difficulties, including declining revenue from its legacy products, compounded the problem. The company could not sustain the direct-to-consumer marketing investment that a stigmatized, niche sexual health product required.

Rights Reversion

AMAG Pharmaceuticals was acquired by Covis Pharma in 2020. Covis subsequently returned the Vyleesi commercial rights to Palatin Technologies. Palatin regained full control but lacked the infrastructure for broad commercial distribution, instead pursuing specialty pharmacy channels and direct-to-patient models. This reversion highlighted a recurring pattern in sexual health drug commercialization: the pharmacology works, but the go-to-market economics are punishing.

Post-Market Safety Obligations and Label Updates

The FDA required several post-marketing commitments at the time of Vyleesi's approval, reflecting unresolved safety questions from the clinical program 3.

Cardiovascular Monitoring Requirements

A post-marketing study evaluating cardiovascular outcomes in women using bremelanotide was among the commitments. The concern stemmed from the transient blood pressure elevations observed in RECONNECT and earlier studies. While no serious cardiovascular events occurred during the key trials, the relatively small sample size (N=1,247 across both studies) and short duration (24 weeks) left the FDA unable to rule out rare but serious outcomes in longer-term use 2.

Hyperpigmentation Monitoring

The label includes a warning about focal hyperpigmentation that may not fully resolve after drug discontinuation. Post-market surveillance was required to characterize the incidence, time course, and reversibility of pigmentary changes in a broader, more racially diverse population than the clinical trial cohort 3.

Interaction With Naltrexone

A labeled drug interaction exists between bremelanotide and naltrexone-containing products. Co-administration significantly reduced the efficacy of oral naltrexone in studies, raising concerns for patients concurrently treated for alcohol use disorder or opioid use disorder. The label contraindicates this combination 3. This interaction is pharmacodynamically mediated: bremelanotide activates melanocortin-4 receptors that functionally oppose opioid receptor blockade in reward pathways.

Ongoing Legal and Regulatory Questions

Several unresolved issues will shape bremelanotide's legal and regulatory trajectory over the next several years.

Off-Label Use Enforcement

PT-141 is widely discussed in men's health and biohacking communities for off-label use in male erectile dysfunction. No approved male indication exists, and Palatin's Phase 2 trials in men were discontinued after the intranasal clinical hold. The FDA has not taken direct enforcement action against prescribers writing off-label prescriptions, consistent with its general stance that off-label prescribing is within physician discretion. Enforcement attention has instead focused on compounding pharmacies marketing PT-141 with explicit claims about male sexual dysfunction 6.

International Regulatory Status

Bremelanotide has not received marketing authorization from the European Medicines Agency (EMA) or any other major regulatory body outside the United States. Palatin has explored partnerships for ex-U.S. Markets but has not filed a Marketing Authorization Application with the EMA. The regulatory pathway in Europe would likely require additional efficacy data, as EMA has historically applied stricter thresholds for patient-reported outcome endpoints in sexual dysfunction indications 8.

Patent Term Extensions

Palatin applied for patent term extension under the Hatch-Waxman Act to compensate for time lost during FDA regulatory review. The Patent and Trademark Office granted a partial extension, adding approximately 2 years to the relevant composition-of-matter patent term. This extension provides additional exclusivity but does not address the broader competitive threat from compounded formulations that fall outside the patent enforcement framework.

What Clinicians Should Know About Prescribing Under Current Constraints

Prescribers considering bremelanotide for premenopausal HSDD should verify cardiovascular status before initiating therapy. Baseline blood pressure must be documented. The drug is contraindicated in uncontrolled hypertension and should not be co-prescribed with naltrexone 3. Patients should be counseled about the 40% nausea rate and the possibility of persistent hyperpigmentation, particularly in patients with darker skin tones. The labeled maximum is 8 doses per month, with no more than 1 dose in any 24-hour period. According to the RECONNECT data, approximately 25% of women in the active-treatment arm reported a clinically meaningful improvement in sexual desire at 24 weeks 2.